 |
|
|
|
 |
|
|
| Article 1 to 10 out of 13 concerning Cenix BioScience GmbH
|
-
Instituto de Medicina Molecular, Cenix BioScience, and Alnylam Pharmaceuticals discover new pathway for malaria infection
(15 Sep 2008)
New research using RNAi technologies published on the first molecular link between malaria and the host cholesterol uptake pathway
Cenix BioScience GmbH, Alnylam Pharmaceuticals, Inc. and the Lisbon-based biomedical research centre Instituto de Medicina Molecular (IMM) announced the publication of their collaborative study in Cell Host & Microbe, describing the discovery and in ...
-
Cenix BioScience Signs Research Agreement with Regulus Therapeutics for miRNA-Targeted Drug Discovery
(23 Jul 2008)
Cenix BioScience GmbH announced that they have signed a research agreement with Regulus Therapeutics LLC to advance the latter's efforts in the discovery of novel therapeutic miRNA modulators.Cenix will apply its expertise in combining high ...
-
Cenix BioScience and CellCentric Sign Framework Research Agreement for RNAi-Based Target Validation.
(26 Mar 2008)
Cenix BioScience GmbH announced that it has signed a framework research agreement to support CellCentric Ltd through cell-based validation of novel therapeutic drug targets for oncology.Cenix will apply its expertise in combining high throughput ...
-
Cenix BioScience Signs Framework Research Agreement with AstraZeneca for RNAi-Based Drug Discovery.
(25 Mar 2008)
Cenix BioScience GmbH (Dresden) announced that it has signed a framework research agreement with AstraZeneca Pharmaceuticals LP to advance the latteršs efforts in the discovery and validation of novel therapeutic drug targets.Cenix will apply its ...
-
Cenix BioScience Expands Usage of Definiens Technology in High-Content Screening
(14 Feb 2008)
Definiens and Cenix BioScience GmbH announced that they have expanded their mutual licensing agreement. This strategic decision confirms the heightened commitment of Cenix to the use of the Definiens technology within its organization. Resulting ...
-
Cenix BioScience and Merck KGaA Sign Framework Agreement for RNAi-Based Drug Discovery
(05 Oct 2006)
Cenix BioScience GmbH and Merck KGaA have signed a framework research agreement securing Cenix services to enhance and accelerate Merck target discovery and validation efforts in oncology, with an option to expand in several human disease ...
-
Cenix BioScience Delivers on Target Discovery Collaboration
(11 Aug 2005)
Cenix BioScience GmbH (Dresden) announced that it has delivered a collection of potential novel therapeutic targets to one of its pharmaceutical partners, Bayer HealthCare AG (Leverkusen). The targets were identified as part of a RNAi-based ...
-
Cenix BioScience and The Instituto de Medicina Molecular Initiate First Genome-Scale RNAi Screen for Novel Malaria Genes
(04 Jul 2005)
Cenix BioScience GmbH (Dresden) and the Instituto de Medicina Molecular (IMM, Lisboa) have initiated a research collaboration to identify human genes required for the malaria infection process, using systematic genome-scale RNAi screening. The ...
-
Definiens and Cenix BioScience Enter into Licensing and Co-Marketing Agreement in High-Content Screening
(10 May 2005)
Definiens and Cenix BioScience announced that they have entered into a licensing and co-marketing agreement. This step represents the formalization of an ongoing and strong relationship, as the two companies have been working together for several ...
-
Cenix BioScience Publishes Comprehensive Genome-Wide RNAi Screen of C. elegans
(31 Mar 2005)
Cenix BioScience GmbH announced the publication of its genome-wide RNAi screen for cell division genes in C. elegans as a full article in Nature magazine. The study, also reviewed by a News & Views feature in the same issue, represents the ...
Additional information
Cenix BioScience GmbH
Dresden, Germany
Company
|
|
|
|
|
|
Top
